What question did this study set out to answer?

To evaluate the methodological, clinical, and ethical issues raised by a retrospective study investigating high-dose, off-label baclofen for the treatment of alcohol dependence.

June 12, 2012Alcohol and AlcoholismOpen Access

Baclofen and Protecting the Patients During Research

View Full Paper

Ask AI

Bookmark

Authors

ABAlain BraillonAmer Sports (France)

Discussion

Member takes

Implication

Critical commentary highlights ethical and safety oversight failures in baclofen trials for high-risk drinkers, suggesting stricter regulatory compliance for off-label pharmacotherapy.

Key Points

To evaluate the methodological, clinical, and ethical issues raised by a retrospective study investigating high-dose, off-label baclofen for the treatment of alcohol dependence.
Critical review of a retrospective analysis involving N=132 high-risk drinkers treated with off-label baclofen in France.
Evaluation of study compliance with standard clinical development pathways, informed consent procedures, professional indemnity insurance coverage, and independent research ethics committee oversight.
The evaluated trial bypassed standard phase II dose-finding protocols, administering an unjustified mean dose of 145 ± 75 mg/day with a maximum dose of 400 mg/day.
Investigators bypassed formal research ethics committee review by designating the study as an audit, leaving informed consent, liability insurance, and non-pharmacological support unverified.
French regulatory authorities originally warned against off-label baclofen due to insufficient evidence, but later permitted dose-adjusted use on an individual basis following emerging observational reports.

Cite This Study

Alain Braillon (2012) studied this question.

synapsesocial.com/papers/6a70c7c2e5469ee92be17617 https://doi.org/10.1093/alcalc/ags060

View Full Paper

Ask AI

Bookmark

Implication

Critical commentary highlights ethical and safety oversight failures in baclofen trials for high-risk drinkers, suggesting stricter regulatory compliance for off-label pharmacotherapy.

Baclofen and Protecting the Patients During Research

Discussion

Member takes

Implication

Key Points

Cite This Study

Baclofen and Protecting the Patients During Research

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider